S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice

ANI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANIP)

$49.96
-0.11 (-0.22%)
(As of 12/5/2023 ET)
Compare
Today's Range
$49.08
$50.26
50-Day Range
$49.27
$65.43
52-Week Range
$36.36
$65.89
Volume
153,786 shs
Average Volume
129,549 shs
Market Capitalization
$1.02 billion
P/E Ratio
96.08
Dividend Yield
N/A
Price Target
$71.67

ANI Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
43.4% Upside
$71.67 Price Target
Short Interest
Healthy
1.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.48
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$6.13 M Sold Last Quarter
Proj. Earnings Growth
-11.73%
From $3.58 to $3.16 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

34th out of 948 stocks

Pharmaceutical Preparations Industry

8th out of 421 stocks


ANIP stock logo

About ANI Pharmaceuticals Stock (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANIP Stock Price History

ANIP Stock News Headlines

Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
A Boring Biopharma Can Be a Good Bet
ANI Pharmaceuticals Inc ANIP
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
ANI Pharmaceuticals Turns To Q3 Profit, Raises Full-year Outlook
Expert Ratings for ANI Pharmaceuticals
See More Headlines
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/14/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
Employees
600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$71.67
High Stock Price Target
$73.00
Low Stock Price Target
$70.00
Potential Upside/Downside
+43.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-47,900,000.00
Pretax Margin
2.94%

Debt

Sales & Book Value

Annual Sales
$316.39 million
Cash Flow
$3.99 per share
Book Value
$17.92 per share

Miscellaneous

Free Float
14,613,000
Market Cap
$1.02 billion
Optionable
Optionable
Beta
0.88
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives















ANIP Stock Analysis - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings
or view top-rated stocks.

What is ANI Pharmaceuticals' stock price target for 2024?

3 brokerages have issued 12 month target prices for ANI Pharmaceuticals' shares. Their ANIP share price targets range from $70.00 to $73.00. On average, they expect the company's share price to reach $71.67 in the next year. This suggests a possible upside of 43.4% from the stock's current price.
View analysts price targets for ANIP
or view top-rated stocks among Wall Street analysts.

How have ANIP shares performed in 2023?

ANI Pharmaceuticals' stock was trading at $40.23 at the beginning of 2023. Since then, ANIP stock has increased by 24.2% and is now trading at $49.96.
View the best growth stocks for 2023 here
.

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 376,800 shares, a decline of 11.0% from the October 31st total of 423,400 shares. Based on an average trading volume of 174,100 shares, the days-to-cover ratio is currently 2.2 days.
View ANI Pharmaceuticals' Short Interest
.

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our ANIP earnings forecast
.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings data on Wednesday, November, 8th. The specialty pharmaceutical company reported $1.27 EPS for the quarter, topping the consensus estimate of $0.84 by $0.43. The specialty pharmaceutical company earned $131.83 million during the quarter, compared to the consensus estimate of $111.92 million. ANI Pharmaceuticals had a trailing twelve-month return on equity of 17.96% and a net margin of 2.98%. ANI Pharmaceuticals's quarterly revenue was up 57.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.46 earnings per share.

What ETFs hold ANI Pharmaceuticals' stock?

ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, October, 5th. The company provided earnings per share (EPS) guidance of $3.62-$4.11 for the period, compared to the consensus EPS estimate of $3.97. The company issued revenue guidance of $425.00 million-$445.00 million, compared to the consensus revenue estimate of $442.97 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Global Alpha Capital Management Ltd. (2.59%), William Blair Investment Management LLC (2.46%), Ranger Investment Management L.P. (2.10%), Invesco Ltd. (1.67%), AIGH Capital Management LLC (1.34%) and Ameriprise Financial Inc. (1.22%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Krista Davis, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends
.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ANIP) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -